Shane Johnson, InMed’s Senior VP and BayMedica’s General Manager, joins the Edison Open Forum Cannabinoids 2021 Event. In his interview, Shane talks about InMed and BayMedica’s complementary cannabinoid manufacturing methods and the importance of non-plant-based approaches, such as biosynthesis, chemical synthesis or hybrid methods, to access meaningful volumes of rare cannabinoids.
In this interview, Shane talks about the multi-factorial reasons for the explosion of interest in cannabinoids – how legalization of cannabis in parts of the U.S. has enabled scientific research into cannabis’ physiological effects and potential significant role in human health and wellness. He expects there will be a broader array of cannabinoids being used as scientific data shows their unique effects, and how each cannabinoid may target specific conditions or symptoms.
The interview touches on the importance of ensuring quality and consistency of cannabinoid products to protect consumers and the need for scientific evidence to support the benefits of these cannabinoids.